Achaogen Stock

AKAOQ

US0044491043

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	+278.79%

12/06/20	Cipla USA Inc. cancelled the acquisition of worldwide right to C-Scape of Achaogen, Inc. (OTCPK:AKAO.Q).	CI
29/05/20	Achaogen, Inc. Went Out of Business	CI

Achaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin is an intravenous aminoglycoside antibiotic. The Company has developed plazomicin by chemically modifying sisomicin, a naturally occurring aminoglycoside, in order to overcome common aminoglycoside resistance mechanisms. The Company has a portfolio of small molecule and antibody programs. The Company's Early Development programs include C-Scape and LpxC.

Employees

Sector

More about the company

Market Cap	639K 549K 518K 472K 883K 61.07M 891K 6.17M 2.38M 30.98M 2.4M 2.35M 98.39M	P/E 2017	-3.39x	P/E 2018	-0.29x
Enterprise Value	19.47M 16.74M 15.8M 14.39M 26.9M 1.86B 27.14M 188M 72.4M 944M 73.1M 71.5M 3B	EV / Sales 2017	28x	EV / Sales 2018	8.66x
Free-Float	-	Yield 2017 *	-	Yield 2018	-

12/06/20	Cipla USA Inc. cancelled the acquisition of worldwide right to C-Scape of Achaogen, Inc. (OTCPK:AKAO.Q).	CI
29/05/20	Achaogen, Inc. Went Out of Business	CI
29/05/20	First Amended Joint Liquidation Plan and Disclosure Statement Approved for Achaogen, Inc.	CI
22/04/20	First Amended Joint Liquidation Plan & Disclosure Statment Filed by Achaogen, Inc. and The Official Committee of Unsecured Creditors	CI
21/04/20	Disclosure Statement Approved on Interim Basis for Achaogen, Inc.	CI
30/03/20	Joint Liquidation Plan & Disclosure Statment Filed by Achaogen, Inc. and The Official Committee of Unsecured Creditors	CI
09/01/20	Motion for Asset Sale Approved for Achaogen, Inc.	CI
29/12/19	Motion for Asset Sale Filed by Achaogen, Inc.	CI
24/09/19	Final DIP Financing Approved for Achaogen, Inc.	CI
29/08/19	Motion for Exclusivity Period Extension Approved For Achaogen, Inc.	CI
13/08/19	First Motion for Exclusivity Period Extension Filed by Achaogen, Inc.	CI
30/07/19	Achaogen, Inc. Announces Management Changes	CI
23/07/19	Motion for Asset Sale Approved for Achaogen, Inc.	CI

	2017	2018
Net sales	11.18M 9.61M 9.07M 8.26M 15.44M 1.07B 15.58M 108M 41.56M 542M 41.96M 41.05M 1.72B	8.73M 7.51M 7.08M 6.45M 12.06M 834M 12.17M 84.35M 32.46M 423M 32.78M 32.06M 1.34B
Net income	-126M -108M -102M -92.86M -174M -12.01B -175M -1.21B -467M -6.09B -472M -461M -19.35B	-187M -160M -151M -138M -258M -17.83B -260M -1.8B -694M -9.04B -700M -685M -28.73B
Net Debt	-143M -123M -116M -106M -197M -13.66B -199M -1.38B -531M -6.93B -536M -525M -22B	18.83M 16.19M 15.28M 13.92M 26.02M 1.8B 26.25M 182M 70.03M 913M 70.7M 69.16M 2.9B

Achaogen Stock

Stocks

AKAOQ

US0044491043

Valuation : Achaogen

Latest news : Achaogen

Financials

Company Profile